NNuage Therapeutics
Nuage Therapeutics is a Barcelona-based biotech spin-off of IRB Barcelona and ICREA that develops small-molecule drugs against intrinsically disordered proteins (IDPs) — targets long considered 'undruggable' — by exploiting biomolecular condensation to render them transiently druggable. Its lead focus is oncogenic transcription factors in cancers such as prostate and aggressive lung cancer, with longer-term interest in neurodegenerative and autoimmune disease. It raised a €12M seed round in June 2023 led by Sofinnova Partners and Asabys Partners, and has since added non-dilutive grant funding (~€2.7M for small-cell lung cancer).
SectorsBiotech, Drug Discovery, Oncology, Life Sciences, Deeptech
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
D
Denes Hnisz
Co-Founder and Board Observer (Group Leader, Max Planck Institute for Molecular Genetics)
J
Judit Anido Folgueira
Co-Founder and former Chief Executive Officer
M
Mateusz Biesaga
Co-Founder and Chief Technology Officer
X
Xavier Salvatella
Co-Founder and Board Member (ICREA Research Professor, IRB Barcelona)
Global models 4
DDewpoint Therapeutics
United States · www.dewpointx.com ↗
Drug-discovery biotech building small-molecule drugs that act on biomolecular condensates, the same platform thesis Nuage uses to drug disordered proteins.
$230MComparable
F
Faze Medicines
United States · www.fazerx.com ↗
Venture-backed biotech that worked on small-molecule drugs targeting condensates in neurodegeneration and cancer; it has since wound down.
$81MComparable
NNereid Therapeutics
United States · www.nereidtx.com ↗
Biotech targeting protein phase separation and condensates to design drugs for undruggable targets, the same scientific model as Nuage.
$50MComparable
TTransition Bio
United Kingdom · www.transitionbio.com ↗
Cambridge spin-out that uses condensate biology and machine learning to find small molecules against intrinsically disordered, undruggable proteins.
$50MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 5
Open as list →
Funding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-26 | Seed (estimated) | €1.8M |
Lead not disclosed
+2 more
|
| 2023-06-20 | Seed | €12M |
Sofinnova Partners, Asabys Partners
+2 more
|
| 2021-09-27 | Seed | — | Asabys Partners |
News 1
Open as list →| Published | Article |
|---|---|
| 2026-09-17 |
Innvierte destina más de €11M en julio y agosto a 9 nuevas coinversiones en capital riesgo ↗
Webcapitalriesgo
2026-09-17 |